causal

Secondary Tweaks Yield Lavish Reward for Little R&D

Drug companies are incentivized to make secondary changes (like adjusting a drug's dosage) rather than inventing new drugs because the R&D investment for a tweak is far less than for initial development while the reward is lavish, and with marginal profit margins around 76% once a drug is in place, a therapeutically meaningless change still produces a large payoff.

causalpending

Speaker

Robin Feldman

Evidence Quote

“The profit margins for companies on their drugs is about 76% in terms of the marginal cost, once you have the drug in place.”

Source

Robin Feldman on Drugs, Money, and Secret Handshakes— EconTalk
Created: 6/13/2026, 12:12:41 AM

Your notes

Loading notes...